PRPH2 families are spread thin, and there is not yet a dedicated PRPH2 patient group you can simply join online. You are not on your own, though: the foundations below run peer-matching programs, the annual PRPH2 workshop brings families together in person, and the wider inherited-retinal-disease community is large and welcoming. The list is in rough order of how much each matters to a newly diagnosed family, and each entry says what to actually do.
For: Every family and patient with an inherited retinal disease in the US
Founded in 1971, FFB is the largest non-governmental funder of inherited retinal disease research in the world, and the connective tissue of the field. For PRPH2 specifically it runs the dedicated PRPH2 and Associated Retinal Diseases program with the Nixon Visions Foundation: eight research awards of up to $500,000 each since 2023, and the only PRPH2-specific workshops ever held (March 2023 and September 2026, both in San Diego). It also runs the My Retina Tracker registry, a Peer Guide program that pairs newly diagnosed people with a trained mentor who has the same condition, roughly 50 local chapters, free webinars, and a phone line staffed by information specialists.
Ways to use it
Enroll in the My Retina Tracker registry in the first weeks after diagnosis.
Call the Information and Resource Specialist line: 1-800-683-5555.
Sign up for the Peer Guide program and find your local chapter.
The patient-family foundation that has done more than any other organization to fund PRPH2-specific research. Janine Nixon noticed changes in her vision for more than 15 years before genetic testing in 2020 found a PRPH2 variant; she and Brandon Nixon then partnered with FFB to build the PRPH2 and Associated Retinal Degenerations program. The foundation set up the Macular Dystrophy-PRPH2 Research Fund at UC San Diego's Shiley Eye Institute in 2021 (the Borooah and Ayyagari labs), has funded six of the eight PARD Science Awards since 2023, and co-organized both PRPH2 workshops with FFB and Shiley. Those workshops are where many PRPH2 families have met each other in person.
Ways to use it
Watch for the next PRPH2 workshop announcement (the last two were three years apart) and register the day it opens; the 2026 event filled and closed to a waitlist.
Sign up for the foundation's updates. The sign-up form lets you choose "PRPH2-related Information" and "PRPH2 Grassroots Community" as topics; the site does not say more about what the community involves.
Questions can go to connect@nixonvisionsfoundation.org; the contact page invites comments and questions.
For: Anyone with a suspected or confirmed inherited retinal disease
FFB's patient registry is the de facto national database that trial sponsors search when a study opens, and enrollment also connects you to a free 285-gene inherited retinal disease panel (run with PreventionGenetics) that includes genetic counseling. As of FFB's March 2026 forum the registry held about 44,000 participants, more than 31,000 of them genotyped. Being in it does not put you in a trial automatically. It makes you findable, which is the step most families miss.
Ways to use it
Enroll online; a clinician or genetic counselor helps populate the clinical fields.
If you have not had genetic testing, request the free panel through the registry.
Upload imaging and functional test results over time so your record stays current.
For: Patients age 4 and up with a variant in a rare inherited retinal disease gene
FFB's largest natural history study, run by the Jaeb Center through about 40 FFB Clinical Consortium sites worldwide, recruiting since May 2023 with primary completion estimated December 2029. It is two studies in one: a one-visit registry tier (one visit, then annual phone calls, capped at 100 participants per gene) and a repeat-visit natural-history tier that opens gene by gene based on funding and registry enrollment. For a dominant gene like PRPH2, a single disease-causing variant qualifies. Why it matters: the missing piece for any PRPH2 trial is progression data, and the FDA's 2026 rare-disease pathways require natural history data in untreated patients. Registry enrollment is the lever families can pull for free.
Ways to use it
Ask your retina specialist whether their center is a Uni-Rare site and request a referral.
Confirm PRPH2 is on the study's RD Rare Gene List at enrollment.
For: Anyone tracking whether a relevant trial has opened
The US registry of clinical studies, and the primary source every secondary tracker copies from. As of September 2026 exactly one PRPH2-specific interventional trial exists in any status (the n-Lorem G208D ASO, active and not recruiting, n=1) and no PRPH2 trial is recruiting; that has been re-verified monthly since April 2026. Gene-agnostic trials, natural history studies, and genotyping networks are the realistic enrollments today.
Ways to use it
Search for PRPH2, cone-rod dystrophy, pattern dystrophy, and gene-agnostic retinitis pigmentosa trials, and read the exclusion criteria, not just the title.
Note that prior gene therapy of any kind is exclusionary in almost every retinal trial; enrolling early in a marginal study can close better doors later.
For: US patients whose variant is rare enough and tractable to a custom antisense oligonucleotide
A nonprofit that designs a custom antisense oligonucleotide (ASO) for one patient's specific mutation and provides it free for life. It sponsors the only PRPH2-targeted therapy ever given to a human: an ASO for the G208D variant, dosed at UCSD since August 2025 (NCT07177196). Its 2026 Nucleic Acids Research report describes more than 35 patients treated with no ASO-related serious adverse events. Two things to know before you get your hopes up: only a research physician at a major referral hospital can submit an application, and the mutation has to be ASO-tractable, which for a dominant gene usually means an allele-selective design that spares the healthy copy.
Ways to use it
Ask your inherited retinal disease specialist whether they can submit an application on your behalf.
Get long-read sequencing with phasing if you carry more than one variant; n-Lorem requires it to design an allele-selective ASO.
For: Families who want an individualized-therapy eligibility read without a physician sponsor
A company that sells the coordination of an individualized genetic medicine: matching a mutation to a modality, then managing the labs, manufacturers, and regulators. Its founder, Stevie Ringel, is an inherited retinal disease patient himself (a KIZ variant with fewer than 200 patients worldwide) who previously ran precision-medicine units at Tempus and GeneDx. The relevant difference from n-Lorem is that Nome takes intake directly from families and the eligibility assessment is free. The honest caveat: as of September 2026 it is a very early-stage company with no dosed patient, no published pricing, and no PRPH2 program.
Ways to use it
Request the free eligibility assessment; a negative answer is still useful information.
Treat it as a second door alongside n-Lorem, not a replacement.
For: Patients willing to travel to Bethesda for research protocols; anyone wanting plain-language explainers
The federal lead for vision research, funder of most US vision science, and home of an intramural clinic in Bethesda, Maryland that runs natural history protocols for rare inherited retinal diseases. The NIH Clinical Center model is unusual: if you are enrolled in a research protocol, it pays for travel and stay. NEI-funded work produced the RPE65 discovery behind Luxturna and funds the NAC Attack Phase 3 trial. Its A-to-Z disease pages and inheritance-pattern explainers are a good starting point for family members.
Ways to use it
Search ClinicalTrials.gov for PRPH2 or cone-rod dystrophy protocols at the NIH Clinical Center, including the NEI genotyping network (NCT06491615).
Ask your specialist whether an NIH natural history protocol fits your situation.
For: Anyone who needs a specialist evaluation, baseline imaging, or variant interpretation
Most people with PRPH2 disease do not need to live near a specialty center, but everyone benefits from at least one consultation at one for variant interpretation, a proper baseline (OCT volume with total macular volume, fundus autofluorescence with a reduced-illumination protocol, ERG), and a frank conversation about the trial pipeline. The closest thing to a PRPH2-specific center in the US is the Borooah Lab at UCSD Shiley Eye Institute. Major US programs include Mass Eye and Ear, Wilmer at Johns Hopkins, Scheie at Penn, Casey at OHSU, UCSF, Baylor, Bascom Palmer, Kellogg at Michigan, Iowa, and UPMC; Moorfields in London and Tübingen in Germany are leading international sites. The right combination is a local ophthalmologist for routine care plus one specialty relationship for the genetics and the research conversation.
Ways to use it
Book one specialty consultation for a baseline and a variant interpretation, even if your local care is good.
Ask the center whether it maintains its own research registry and whether it is an FFB Clinical Consortium site.
For: Adults with vision loss, and explicitly parents and family members
A free, phone-based peer support program run through the Rutgers School of Health Professions, staffed by trained peer specialists who themselves live with vision loss. It offers one-to-one calls, virtual groups, an eight-week workshop for the newly diagnosed on coping, assistive technology, mobility, and self-advocacy, and Spanish-language support. About a third of people with vision loss experience clinically significant depression or anxiety, and this is one of the few free services built for that. Parents are explicitly welcome, and can be matched with adults who grew up with the same condition.
Ways to use it
Call 833-932-3931 or email eye2eye@shp.rutgers.edu. Open to anyone in the US, free.
For: Families who want a membership community and youth programs
The largest membership organization of blind and low-vision people in the US. Its National Organization of Parents of Blind Children runs an annual convention with a kids' track, year-round community, and state chapters. Youth programs include BELL Academy summer braille enrichment, youth events, and mentorship with blind adult role models.
Ways to use it
Find your state affiliate and the parents' division.
Look at BELL Academy if your child is school age and could benefit from summer braille immersion.
For: Families building a services and technology plan, especially in the US
An Arizona nonprofit focused on childhood blindness. Its free education hub, launched July 2026, profiles 53 inherited retinal diseases and 125 genes and includes the one thing most resource lists lack: a state-by-state services directory, alongside adaptive-technology material and a treatment-pipeline tracker. In June 2026 it committed $1 million to gene-agnostic therapy research through FFB. Use it for the services directory; for trial status, go to ClinicalTrials.gov directly, because the hub's pipeline data is derived from it.
Ways to use it
Look up your state in the services directory when building an IEP or low-vision technology plan.
For: Parents of blind and low-vision children in the US
The single best free starting hub for a family navigating a new pediatric vision diagnosis. Built by the American Foundation for the Blind and the National Association of Parents of Children with Visual Impairments, now hosted by APH. Browse by age from birth to transition; sections on IFSPs (Individualized Family Service Plans, the pre-school version of an IEP), IEPs (Individualized Education Programs, the legal plan a school writes for a child with a disability), the Expanded Core Curriculum (the extra skills, such as braille and mobility, taught to children with visual impairment), braille and literacy, technology, daily living, and an After the Diagnosis guide; plus parent-moderated message boards and virtual support groups.
Ways to use it
Bookmark it as your hub and read the After the Diagnosis section first.
Register your child with Bookshare (free accessible ebooks for K-12 students) through their teacher of the visually impaired.
For: Families and educators anywhere, via online programs
Massachusetts-based with national reach. Perkins eLearning offers free courses for parents and educators; the resource library is searchable by topic; Paths to Literacy (with APH) covers teaching reading and writing to children with visual impairment; and the Perkins Library provides free accessible books and audio. Families outside New England can use nearly all of it.
Ways to use it
Browse the resource library and Paths to Literacy when planning early literacy.
Look into the free parent webinars and eLearning courses.
For: Families outside the US, or with international ties
A patient-led global umbrella of 43 member organizations across six continents, all focused on inherited and rare retinal diseases. Its country-member finder connects you to your national organization (FFB in the US, Retina UK, Fighting Blindness Ireland, PRO RETINA Germany, Retina Australia, and others), and its education hub has plain-language explainers on genetics, clinical trials, gene therapy, and regulatory approval. The biennial Retina International World Congress is one of the few places to see the global research community present to patients in patient-friendly language.
Ways to use it
Use the member finder to locate the organization for your country.
Read the position papers on gene therapy access and genetic testing if you are advocating locally.
For: UK families, and anyone who wants well-written English-language materials
The only UK charity dedicated solely to inherited sight loss. Its helpline (0300 111 4000, weekdays 9:30 to 21:30) offers practical and emotional support; it publishes condition-specific information packs including cone-rod dystrophy; and its Unlock Genetics and Discover Wellbeing programs are unusually good on genetic testing and on the mental-health side of progressive sight loss. For US families it is a useful supplement to FFB.
Ways to use it
Request the cone-rod dystrophy or pattern dystrophy information pack.
Use the Talk and Support befriending service if you want to speak with someone living with an inherited retinal disease.
A note on what this list is notIt is not an endorsement and it is not complete. Organizations were included because their services are relevant to a PRPH2 family, and the descriptions reflect their public statements as of September 2026. If you run one and something is wrong, the About page explains how to get it fixed.